Accendra Health (ACH) Q1 2026 Earnings Transcript

Accendra Health reported Q1 adjusted EBITDA of $58 million, in line with expectations, while revenue fell 6.8% but would have risen about 1% excluding the exited large commercial payor. Management reaffirmed 2026 revenue and EBITDA guidance and highlighted improving sleep category momentum, an exclusive multiyear soft-goods payor extension, and a major balance-sheet refinancing that pushes maturities to 2032-2033 and reduces debt by up to $115 million. Liquidity remains solid with $337 million of cash, $195 million of revolver availability, and no covenant issues.

Analysis

The market is likely underestimating how much of this quarter was a reset rather than a stumble. Once the exited commercial payor drops out of the comp base, the business should mechanically re-accelerate into a cleaner growth rate, while the cost takeout from that same exit should continue to flow through for several quarters as SG&A annualizes lower. The bigger second-order issue is that management just removed a major overhang on the equity, but replaced it with a more levered, higher-coupon capital structure, so the stock becomes less about "survived the transition" and more about whether incremental operating leverage can outrun roughly $20M of annualized additional interest burden.

The sleep platform is the key swing factor because it has the highest chance of compounding without needing external payor wins to cooperate. The early signal here is not just volume growth, but better adherence and larger order baskets, which should improve lifetime value and reduce churn; if the center-of-excellence rollout scales without service degradation, this becomes a durable margin lever, not just a marketing initiative. That matters because the company needs a cleaner mix shift away from lower-yield diabetes and lagging respiratory growth toward categories where workflow control can translate directly into conversion and retention gains.

Credit investors should view the transaction as a maturity-extension event first and a deleveraging event second. Pushing the wall out to the early 2030s meaningfully reduces refinancing risk, but the new structure also locks in higher cash interest just as free cash flow is still seasonally weak and propped up by one-time items rolling off. The equity story therefore hinges on execution in the next two quarters: if the sleep ramp, SG&A reduction, and new payor onboarding all show up simultaneously, the stock can rerate; if not, the market will likely re-focus on leverage and cash conversion rather than headline growth.

Key Decisions for Investors

• Long OMI on a 3-6 month horizon via common stock or call spreads: the setup is favorable if the market re-prices away the exited-payor overhang and toward cleaner comp growth; target 15-25% upside if sleep and SG&A trends hold, but cut if Q2 shows no sequential margin expansion.
• Pair trade: long OMI / short a weaker home-health or DME peer with more refinancing risk and less payor visibility: Accendra's maturity extension should narrow the discount to higher-quality recurring-revenue healthcare names even if absolute upside is modest.
• Buy OMI 2029/2030 debt or upper-maturity notes on weakness: the refinancing materially reduces near-term default/refi risk, while the improved tenor should compress spreads; risk/reward is better in credit than equity if the operating ramp is slower than expected.
• If trading equity vol, sell near-dated puts into post-restructuring de-risking: the balance sheet event and guidance reaffirmation should damp downside skew over the next 30-45 days, but size carefully because higher interest expense caps upside if execution lags.
• Monitor for a tactical short if Q2 free cash flow remains negative after non-recurring items: that would signal the equity thesis is becoming dependent on second-half seasonality rather than durable conversion, which is where rerating multiples usually fail.